LLY News and Press, Eli Lilly and Company From 04/23/24

2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...

2024-04-23 11:26:33 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk Remains The Better Buy After A Moderate Pullback Eli Lilly And The Alzheimer's Dilemma (Rating Upgrade) Wall Street Lunch: Lilly In Limelight Eli Lilly buys injectable medicine manufact...

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...

2024-04-23 04:34:38 ET Summary VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF has been in an uptrend since late last year and is currently trading at a level that presents a buying opportunity. The ...

2024-04-22 16:25:01 ET More on S&P 500 Index: Why AI Stocks Could Go Boom Fed's Commercial Banking Report Shows Economic Headwinds, But Deposit Growth Bucks Trend S&P 500: Capitulation? Week Starting 22nd April (Technical Analysis) Nasdaq, S&P, an...

2024-04-22 13:25:00 ET Summary UBS sounded a warning on its list of Big 6 tech companies, cut rating on them to "Neutral". Tesla stock hits a new 52-week low after troubling developments on car pricing. Check out Goldman's picks top capex and R&D stocks. Listen b...

2024-04-22 10:20:45 ET Eli Lilly ( NYSE: LLY ) has agreed to acquire a manufacturing facility from Nexus Pharmaceuticals to further expand its global parenteral (injectable) product manufacturing network and support increased demand for its drugs.... Read the full article ...

2024-04-22 09:00:00 ET Summary NVO continues to be rated as a Buy, with the stock already charting an impressive +16.1% rally over the past three months, well outperforming the wider market at +4.8%. The management recently announced multiple expansions in its manufacturing/fill f...

(NewsDirect) Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was...

2024-04-22 00:58:35 ET Summary The FDA has convened an advisory panel to discuss the safety and efficacy of Eli Lilly's anti-amyloid antibody drug donanemab. Approval of donanemab could have a modestly positive impact on LLY stock, while denial could lead to a substantial (but not...